Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.
de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL. de Jonge MJA, et al. Among authors: verheijen rb. Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1. Target Oncol. 2019. PMID: 30756308 Free PMC article. Clinical Trial.
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.
Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP. Verheijen RB, et al. Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0. Target Oncol. 2019. PMID: 30742245 Free PMC article. Clinical Trial.
Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.
Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group. Verheijen RB, et al. Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. doi: 10.1158/1078-0432.CCR-16-1255. Epub 2016 Jul 28. Clin Cancer Res. 2016. PMID: 27470967
Individualized Pazopanib Dosing-Response.
Verheijen RB, Huitema AD, Steeghs N. Verheijen RB, et al. Clin Cancer Res. 2016 Dec 15;22(24):6299. doi: 10.1158/1078-0432.CCR-16-2297. Clin Cancer Res. 2016. PMID: 27980023 No abstract available.
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients.
Groenland SL, van Eerden RAG, Verheijen RB, de Vries N, Thijssen B, Rosing H, Beijnen JH, Koolen SLW, Mathijssen RHJ, Huitema ADR, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Groenland SL, et al. Among authors: verheijen rb. Clin Pharmacokinet. 2020 Jul;59(7):941-948. doi: 10.1007/s40262-020-00863-5. Clin Pharmacokinet. 2020. PMID: 32020530 Clinical Trial.
33 results